Comparison of efficacy and safety of Aripiprazole and Ziprasidone in the treatment of schizophrenia

Objective:To compare efficacy and safety of Aripiprazo1e and Ziprasidone in the treatment of schizophrenia.Methods:80 patients with schizophrenia by ICD10 were randomly allocated to two groups treated with Aripiprazo1e or Ziprasidone for 8 weeks.The Positive and Negative Syndrom Scale(PANSS) and Treatment Emergent Symptoms Scale(TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment.Results:The total effective rates for the Aripiprazole and Ziprasidone groups were similar after 8 weeks(P0.05).There was no significant difference between the two groups(P0.05).Incidence of adverse effects in the Aripiprazole group was lower than that in the Ziprasidone group,but the difference was not Significant(P0.05).Their side effects were not serious,and patients often had good torlerabi1ity for them.Conclusion:The results suggest that Aripiprazo1e is as effective as Ziprasidone for the treatment of schizophrenia,and two agents have low side effects profile.